This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Pyrko, P. Articles by Lee, A. S. Search for Related Content PubMed PubMed Citation Articles by Pyrko, P. Articles by Lee, A. S.

The Unfolded Protein Response Regulator GRP78/BiP as a Novel Target for Increasing Chemosensitivity in Malignant Gliomas

Departments of ¹ Pathology, ² Molecular Microbiology and Immunology, ³ Neurosurgery, ⁴ Biochemistry and Molecular Biology, and ⁵ University of Southern California/Norris Comprehensive Cancer Center, University of Southern California Keck School of Medicine, Los Angeles, California

Requests for reprints: Amy S. Lee, Department of Biochemistry and Molecular Biology, University of Southern California/Norris Comprehensive Cancer Center, University of Southern California Keck School of Medicine, 1441 Eastlake Avenue, Los Angeles, CA 90033. Phone: 323-865-0507; Fax: 323-865-0094; E-mail: amylee{at}usc.edu or Thomas C. Chen, Department of Neurosurgery, University of Southern California Keck School of Medicine, 1200 N. State Street, #5046, Los Angeles, CA 90033. Phone: 323-226-7421; Fax: 323-226-7833; E-mail: tcchen{at}usc.edu.

Poor chemosensitivity and the development of chemoresistance remain major obstacles to successful chemotherapy of malignant gliomas. GRP78 is a key regulator of the unfolded protein response (UPR). As a Ca²⁺-binding molecular chaperone in the endoplasmic reticulum (ER), GRP78 maintains ER homeostasis, suppresses stress-induced apoptosis, and controls UPR signaling. We report here that GRP78 is expressed at low levels in normal adult brain, but is significantly elevated in malignant glioma specimens and human malignant glioma cell lines, correlating with their rate of proliferation. Down-regulation of GRP78 by small interfering RNA leads to a slowdown in glioma cell growth. Our studies further reveal that temozolomide, the chemotherapeutic agent of choice for treatment of malignant gliomas, leads to induction of CHOP, a major proapoptotic arm of the UPR. Knockdown of GRP78 in glioblastoma cell lines induces CHOP and activates caspase-7 in temozolomide-treated cells. Colony survival assays further establish that knockdown of GRP78 lowers resistance of glioma cells to temozolomide, and, conversely, overexpression of GRP78 confers higher resistance. Knockdown of GRP78 also sensitizes glioma cells to 5-fluorouracil and CPT-11. Treatment of glioma cells with (–)-epigallocatechin gallate, which targets the ATP-binding domain of GRP78 and blocks its protective function, sensitizes glioma cells to temozolomide. These results identify a novel chemoresistance mechanism in malignant gliomas and show that combination of drugs capable of suppressing GRP78 with conventional agents such as temozolomide might represent a novel approach to eliminate residual tumor cells after surgery and increase the effectiveness of malignant glioma chemotherapy. [Cancer Res 2007;67(20):9809–16]

This article has been cited by other articles:

				D. Xu, R. E. Perez, M. H. Rezaiekhaligh, M. Bourdi, and W. E. Truog Knockdown of ERp57 increases BiP/GRP78 induction and protects against hyperoxia and tunicamycin-induced apoptosis Am J Physiol Lung Cell Mol Physiol, July 1, 2009; 297(1): L44 - L51. [Abstract] [Full Text] [PDF]

				B. C. McFarland, J. Stewart Jr., A. Hamza, R. Nordal, D. J. Davidson, J. Henkin, and C. L. Gladson Plasminogen Kringle 5 Induces Apoptosis of Brain Microvessel Endothelial Cells: Sensitization by Radiation and Requirement for GRP78 and LRP1 Cancer Res., July 1, 2009; 69(13): 5537 - 5545. [Abstract] [Full Text] [PDF]

				E. B. Golden, P. Y. Lam, A. Kardosh, K. J. Gaffney, E. Cadenas, S. G. Louie, N. A. Petasis, T. C. Chen, and A. H. Schonthal Green tea polyphenols block the anticancer effects of bortezomib and other boronic acid-based proteasome inhibitors Blood, June 4, 2009; 113(23): 5927 - 5937. [Abstract] [Full Text] [PDF]

				S. Saito, A. Furuno, J. Sakurai, A. Sakamoto, H.-R. Park, K. Shin-ya, T. Tsuruo, and A. Tomida Chemical Genomics Identifies the Unfolded Protein Response as a Target for Selective Cancer Cell Killing during Glucose Deprivation Cancer Res., May 15, 2009; 69(10): 4225 - 4234. [Abstract] [Full Text] [PDF]

				P. Baumeister, D. Dong, Y. Fu, and A. S. Lee Transcriptional induction of GRP78/BiP by histone deacetylase inhibitors and resistance to histone deacetylase inhibitor-induced apoptosis Mol. Cancer Ther., May 1, 2009; 8(5): 1086 - 1094. [Abstract] [Full Text] [PDF]

				A. Bressenot, S. Marchal, L. Bezdetnaya, J. Garrier, F. Guillemin, and F. Plenat Assessment of Apoptosis by Immunohistochemistry to Active Caspase-3, Active Caspase-7, or Cleaved PARP in Monolayer Cells and Spheroid and Subcutaneous Xenografts of Human Carcinoma J. Histochem. Cytochem., April 1, 2009; 57(4): 289 - 300. [Abstract] [Full Text] [PDF]

				D. M. Schewe and J. A. Aguirre-Ghiso Inhibition of eIF2{alpha} Dephosphorylation Maximizes Bortezomib Efficiency and Eliminates Quiescent Multiple Myeloma Cells Surviving Proteasome Inhibitor Therapy Cancer Res., February 15, 2009; 69(4): 1545 - 1552. [Abstract] [Full Text] [PDF]

				C. C. Jiang, Z. G. Mao, K. A. Avery-Kiejda, M. Wade, P. Hersey, and X. D. Zhang Glucose-regulated protein 78 antagonizes cisplatin and adriamycin in human melanoma cells Carcinogenesis, February 1, 2009; 30(2): 197 - 204. [Abstract] [Full Text] [PDF]

				Y. Fu, S. Wey, M. Wang, R. Ye, C.-P. Liao, P. Roy-Burman, and A. S. Lee Pten null prostate tumorigenesis and AKT activation are blocked by targeted knockout of ER chaperone GRP78/BiP in prostate epithelium PNAS, December 9, 2008; 105(49): 19444 - 19449. [Abstract] [Full Text] [PDF]

				T. Racek, S. Buhlmann, F. Rust, S. Knoll, V. Alla, and B. M. Putzer Transcriptional Repression of the Prosurvival Endoplasmic Reticulum Chaperone GRP78/BIP by E2F1 J. Biol. Chem., December 5, 2008; 283(49): 34305 - 34314. [Abstract] [Full Text] [PDF]

				D. R. Fels, J. Ye, A. T. Segan, S. J. Kridel, M. Spiotto, M. Olson, A. C. Koong, and C. Koumenis Preferential Cytotoxicity of Bortezomib toward Hypoxic Tumor Cells via Overactivation of Endoplasmic Reticulum Stress Pathways Cancer Res., November 15, 2008; 68(22): 9323 - 9330. [Abstract] [Full Text] [PDF]

				J. J. Virrey, D. Dong, C. Stiles, J. B. Patterson, L. Pen, M. Ni, A. H. Schonthal, T. C. Chen, F. M. Hofman, and A. S. Lee Stress Chaperone GRP78/BiP Confers Chemoresistance to Tumor-Associated Endothelial Cells Mol. Cancer Res., August 1, 2008; 6(8): 1268 - 1275. [Abstract] [Full Text] [PDF]

				D. Dong, M. Ni, J. Li, S. Xiong, W. Ye, J. J. Virrey, C. Mao, R. Ye, M. Wang, L. Pen, et al. Critical Role of the Stress Chaperone GRP78/BiP in Tumor Proliferation, Survival, and Tumor Angiogenesis in Transgene-Induced Mammary Tumor Development Cancer Res., January 15, 2008; 68(2): 498 - 505. [Abstract] [Full Text] [PDF]